Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666159 · ClinicalTrials.gov registry record · Phase 4
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis
A Phase 4 study of Dermatitis, Atopic, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 226
- Enrollment target
- 12
- Study locations
NCT00666159: Completed Phase 4 study of Dermatitis, Atopic, sponsored by Astellas Pharma.
NCT00666159 is a Phase 4 study of Dermatitis, Atopic that has completed, run by Astellas Pharma. The registered enrollment target is 226 participants, below the 389-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (42% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666159, a Phase 4 study of Dermatitis, Atopic, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 226 participants
- Enrollment target
- 12
- Study locations
Study Summary
Comparison of Protopic Ointment to Elidel Cream to assess the safety and efficacy in pediatric patients with Atopic Dermatitis
Conditions Studied
Interventions
- DRUG tacrolimus ointment
- DRUG pimecrolimus cream
Study Locations (12)
North Carolina
- - Chapel Hill
- - Wilmington
- - Winston-Salem
Florida
- - Miami
- - Miami
Connecticut
- - New Haven
Illinois
- - Chicago
Massachusetts
- - Boston
Michigan
- - Clinton Township
Nebraska
- - Omaha
Nevada
- - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2002-12 |
| Est. Completion | 2003-05 |
| Phase | Phase 4 |
What the finished NCT00666159 record still lists
NCT00666159 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 389-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which tacrolimus ointment is the first listed.
NCT00666159 lists 12 locations in 9 states (North Carolina, Florida, Connecticut).
Frequently Asked Questions
What is clinical trial NCT00666159 about?
NCT00666159 is a clinical study titled "Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis". Comparison of Protopic Ointment to Elidel Cream to assess the safety and efficacy in pediatric patients with Atopic Dermatitis
What is the current status of trial NCT00666159?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2002-12. Estimated completion is 2003-05.
What conditions does trial NCT00666159 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT00666159?
The interventions under investigation include: tacrolimus ointment (DRUG), pimecrolimus cream (DRUG).
Who is sponsoring clinical trial NCT00666159?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00666159 being conducted?
This trial has 12 study locations across Connecticut, Florida, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00666159's enrollment target sits among peer trials
226 15th of 29 higher than 15 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 4
-
Topical Steroid Formulation and Wet Wraps
COMPLETED · Phase 4
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia